{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:06:29Z","timestamp":1793048789393,"version":"4.5.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.iac.2023.04.011","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T03:24:19Z","timestamp":1689650659000},"page":"627-649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["World Health Organization Classification and Diagnosis of Mastocytosis"],"prefix":"10.1016","volume":"43","author":[{"given":"Peter","family":"Valent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Sotlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Horny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Arock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.iac.2023.04.011_bib1","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.iac.2023.04.011_bib2","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/eji.201040559","article-title":"Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity","volume":"40","author":"Galli","year":"2010","journal-title":"Eur J Immunol"},{"issue":"2","key":"10.1016\/j.iac.2023.04.011_bib3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.iac.2023.04.011_bib4","doi-asserted-by":"crossref","first-page":"10743","DOI":"10.7150\/thno.46719","article-title":"Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts","volume":"10","author":"Valent","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.iac.2023.04.011_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-immunol-071719-094903","article-title":"Mast cells in inflammation and disease: recent progress and ongoing concerns","volume":"38","author":"Galli","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.iac.2023.04.011_bib6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0065-2776(08)60879-2","article-title":"Cell surface structures on human basophils and mast cells: biochemical and functional characterization","volume":"52","author":"Valent","year":"1992","journal-title":"Adv Immunol"},{"issue":"4","key":"10.1016\/j.iac.2023.04.011_bib7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1056\/NEJM199301283280408","article-title":"New concepts about the mast cell","volume":"328","author":"Galli","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.iac.2023.04.011_bib8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000101711","article-title":"Mastocytosis: state of the art","volume":"74","author":"Horny","year":"2007","journal-title":"Pathobiology"},{"issue":"4","key":"10.1016\/j.iac.2023.04.011_bib9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/ehm.10.42","article-title":"Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives","volume":"3","author":"Arock","year":"2010","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"10.1016\/j.iac.2023.04.011_bib10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.iac.2014.02.003","article-title":"Diagnostic criteria and classification of mastocytosis in 2014","volume":"34","author":"Akin","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1","key":"10.1016\/j.iac.2023.04.011_bib11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology","volume":"137","author":"Hartmann","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2023.04.011_bib12","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the classification and treatment of mastocytosis: current status and outlook toward the future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.iac.2023.04.011_bib13","first-page":"323","article-title":"Rare forms of urticaria","volume":"2","author":"Nettleship","year":"1869","journal-title":"Br Med J"},{"key":"10.1016\/j.iac.2023.04.011_bib14","first-page":"166","article-title":"Beitr\u00e4ge zur Kenntnis der granulierten Bindegewebszellen und der eosinophilen Leukocyten","volume":"7","author":"Ehrlich","year":"1879","journal-title":"Arch Anat Physiol"},{"key":"10.1016\/j.iac.2023.04.011_bib15","first-page":"9","article-title":"Beitrage zur Anatomie und Pathogeneses der Urticaria Simplex und Pigmentosa","volume":"3","author":"Unna","year":"1887","journal-title":"Monatschr Prakt Dermatol Suppl Dermatol"},{"key":"10.1016\/j.iac.2023.04.011_bib16","first-page":"426","article-title":"Urticaria pigmentosa; a report of a case with autopsy","volume":"48","author":"Ellis","year":"1949","journal-title":"ArchPathol"},{"issue":"2","key":"10.1016\/j.iac.2023.04.011_bib17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000048185","article-title":"Smouldering mastocytosis: a novel subtype of systemic mastocytosis with slow progression","volume":"127","author":"Valent","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"issue":"5","key":"10.1016\/j.iac.2023.04.011_bib18","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/path.2677","article-title":"Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD)","volume":"220","author":"Sotlar","year":"2010","journal-title":"J\u00a0Pathol"},{"issue":"8","key":"10.1016\/j.iac.2023.04.011_bib19","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1182\/blood-2012-07-442400","article-title":"Mast cell leukemia","volume":"121","author":"Georgin-Lavialle","year":"2013","journal-title":"Blood"},{"issue":"40","key":"10.1016\/j.iac.2023.04.011_bib20","doi-asserted-by":"crossref","first-page":"66299","DOI":"10.18632\/oncotarget.11812","article-title":"Mast cell sarcoma: new cases and literature review","volume":"7","author":"Monnier","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.iac.2023.04.011_bib21","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0889-8588(05)70300-2","article-title":"Serum tryptase and the laboratory diagnosis of systemic mastocytosis","volume":"14","author":"Schwartz","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"issue":"23","key":"10.1016\/j.iac.2023.04.011_bib22","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci (USA)"},{"issue":"3","key":"10.1016\/j.iac.2023.04.011_bib23","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng0396-312","article-title":"Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm","volume":"12","author":"Longley","year":"1996","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.iac.2023.04.011_bib24","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/mp.53.4.188","article-title":"Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia","volume":"53","author":"Sotlar","year":"2000","journal-title":"Mol Pathol"},{"issue":"2","key":"10.1016\/j.iac.2023.04.011_bib25","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1046\/j.1365-2141.2001.02783.x","article-title":"Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis","volume":"113","author":"Fritsche-Polanz","year":"2001","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.iac.2023.04.011_bib26","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/00000478-199809000-00013","article-title":"Diagnostic value of immunostaining for tryptase in patients with mastocytosis","volume":"22","author":"Horny","year":"1998","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1016\/j.iac.2023.04.011_bib27","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood.V91.8.2731.2731_2731_2736","article-title":"Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications","volume":"91","author":"Escribano","year":"1998","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.iac.2023.04.011_bib28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0145-2126(01)00041-8","article-title":"Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis","volume":"25","author":"Sperr","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.iac.2023.04.011_bib29","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000059404","article-title":"Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease","volume":"128","author":"Sperr","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.iac.2023.04.011_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000024214","article-title":"Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998","volume":"120","author":"Valent","year":"1999","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.iac.2023.04.011_bib31","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.iac.2023.04.011_bib32","series-title":"World Health Organization (WHO) classification of Tumours. Pathology & genetics. Tumours of Haematopoietic and lymphoid tissues","first-page":"291","article-title":"Mastocytosis (mast cell disease)","author":"Valent","year":"2001"},{"key":"10.1016\/j.iac.2023.04.011_bib33","series-title":"World Health Organization (WHO) classification of Tumours. Pathology & genetics. Tumours of Haematopoietic and lymphoid tissues","first-page":"54","article-title":"Mastocytosis (mast cell disease)","author":"Horny","year":"2008"},{"key":"10.1016\/j.iac.2023.04.011_bib34","series-title":"WHO classification of Tumours of Haematopoietic and lymphoid tissues","first-page":"62","article-title":"Mastocytosis","author":"Horny","year":"2017"},{"key":"10.1016\/j.iac.2023.04.011_bib35","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.iac.2023.04.011_bib36","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.2019000932","article-title":"New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis","volume":"135","author":"Reiter","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.iac.2023.04.011_bib37","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","article-title":"Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal","volume":"5","author":"Valent","year":"2021","journal-title":"Hemasphere"},{"issue":"7","key":"10.1016\/j.iac.2023.04.011_bib38","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.iac.2023.04.011_bib39","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3324\/haematol.2010.031690","article-title":"Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis","volume":"96","author":"Wilson","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.iac.2023.04.011_bib40","doi-asserted-by":"crossref","first-page":"e43090","DOI":"10.1371\/journal.pone.0043090","article-title":"Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis","volume":"7","author":"Traina","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.iac.2023.04.011_bib41","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.iac.2023.04.011_bib42","doi-asserted-by":"crossref","first-page":"e85362","DOI":"10.1371\/journal.pone.0085362","article-title":"ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases","volume":"9","author":"Damaj","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.iac.2023.04.011_bib43","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.iac.2023.04.011_bib44","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s41375-018-0346-z","article-title":"KIT D816 mutated\/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis","volume":"33","author":"Jawhar","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.iac.2023.04.011_bib45","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/gcc.22526","article-title":"Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis","volume":"57","author":"Naumann","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.iac.2023.04.011_bib46","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/ajh.24426","article-title":"Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival","volume":"91","author":"Pardanani","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.iac.2023.04.011_bib47","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood.2018886507","article-title":"Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis","volume":"134","author":"Mu\u00f1oz-Gonz\u00e1lez","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.iac.2023.04.011_bib48","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7150\/thno.51872","article-title":"Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis","volume":"11","author":"Kluin-Nelemans","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.iac.2023.04.011_bib49","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2352-3026(19)30166-8","article-title":"International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study","volume":"6","author":"Sperr","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.iac.2023.04.011_bib50","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1200\/JCO.19.00640","article-title":"MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis","volume":"37","author":"Jawhar","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.iac.2023.04.011_bib51","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(20)30400-2","article-title":"Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study","volume":"8","author":"Mu\u00f1oz-Gonz\u00e1lez","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.iac.2023.04.011_bib52","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaip.2013.06.014","article-title":"Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations","volume":"1","author":"Bonadonna","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.iac.2023.04.011_bib53","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis","volume":"32","author":"Ustun","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.iac.2023.04.011_bib54","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/leu.2016.30","article-title":"Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia","volume":"30","author":"Alvarez-Twose","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.iac.2023.04.011_bib55","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2023.04.011_bib56","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1093\/annonc\/mdx290","article-title":"Midostaurin: a magic bullet that blocks mast cell expansion and activation","volume":"28","author":"Valent","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.iac.2023.04.011_bib57","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/cea.13592","article-title":"Omalizumab in the treatment of adult patients with mastocytosis: A systematic review","volume":"50","author":"Jendoubi","year":"2020","journal-title":"Clin Exp Allergy"},{"issue":"12","key":"10.1016\/j.iac.2023.04.011_bib58","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat Med"},{"issue":"21","key":"10.1016\/j.iac.2023.04.011_bib59","doi-asserted-by":"crossref","first-page":"5750","DOI":"10.1182\/bloodadvances.2022007539","article-title":"Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis","volume":"6","author":"Reiter","year":"2022","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.iac.2023.04.011_bib60","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/s41375-022-01615-z","article-title":"Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis","volume":"36","author":"Reiter","year":"2022","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.iac.2023.04.011_bib61","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1182\/blood.2021014612","article-title":"Avapritinib for advanced systemic mastocytosis","volume":"140","author":"Gotlib","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.iac.2023.04.011_bib62","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.iac.2023.04.011_bib63","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: Proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2023.04.011_bib64","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/all.12126","article-title":"Mast cell activation syndromes: definition and classification","volume":"68","author":"Valent","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2023.04.011_bib65","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.3390\/ijms21239030","article-title":"Diagnosis, classification and management of mast cell activation syndromes (MCAS) in the era of personalized medicine","volume":"21","author":"Valent","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.iac.2023.04.011_bib66","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.iac.2023.04.011_bib67","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.iac.2018.04.003","article-title":"Hereditary Alpha Tryptasemia: Genotyping and Associated Clinical Features","volume":"38","author":"Lyons","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.iac.2023.04.011_bib68","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaci.2020.06.035","article-title":"Heritable risk for severe anaphylaxis associated with increased alpha-tryptase-encoding germline copy number at TPSAB1","volume":"147","author":"Lyons","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2023.04.011_bib69","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.2020006157","article-title":"Hereditary \u03b1 tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis","volume":"137","author":"Greiner","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.iac.2023.04.011_bib70","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2008.11.018","article-title":"Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels","volume":"123","author":"Bonadonna","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2023.04.011_bib71","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/ACI.0b013e32833b280c","article-title":"Mastocytosis and insect venom allergy","volume":"10","author":"Bonadonna","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2023.04.011_bib72","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000329218","article-title":"Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience","volume":"157","author":"Wimazal","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.iac.2023.04.011_bib73","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jaci.2012.10.052","article-title":"Systemic mastocytosis as a risk factor for severe hymenoptera sting-induced anaphylaxis","volume":"131","author":"Alvarez-Twose","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2023.04.011_bib74","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2014.11.035","article-title":"Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels","volume":"136","author":"Zanotti","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2023.04.011_bib75","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.iac.2023.04.011_bib76","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A\u00a0novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.iac.2023.04.011_bib77","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaci.2015.05.008","article-title":"Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis","volume":"137","author":"\u00c1lvarez-Twose","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2023.04.011_bib78","doi-asserted-by":"crossref","first-page":"68950","DOI":"10.18632\/oncotarget.10711","article-title":"Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature","volume":"8","author":"Alvarez-Twose","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.iac.2023.04.011_bib79","doi-asserted-by":"crossref","first-page":"e4934","DOI":"10.1097\/MD.0000000000004934","article-title":"Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: a case report","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine (Baltim)"},{"issue":"11","key":"10.1016\/j.iac.2023.04.011_bib80","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.iac.2023.04.011_bib81","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/all.12436","article-title":"Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis","volume":"69","author":"Valent","year":"2014","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.iac.2023.04.011_bib82","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.jaip.2022.03.007","article-title":"Personalized management strategies in mast cell disorders: ECNM-AIM user's guide for daily clinical practice","volume":"10","author":"Valent","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.iac.2023.04.011_bib83","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.jid.2020.12.030","article-title":"Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis","volume":"141","author":"Aberer","year":"2021","journal-title":"Invest Dermatol"},{"key":"10.1016\/j.iac.2023.04.011_bib84","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jaci.2015.05.034","article-title":"Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis","volume":"136","author":"Wiechers","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2023.04.011_bib85","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/modpathol.2010.224","article-title":"Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis","volume":"24","author":"Sotlar","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.iac.2023.04.011_bib86","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3109\/10428194.2010.550072","article-title":"Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms","volume":"52","author":"Valent","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.iac.2023.04.011_bib87","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/his.12221","article-title":"CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis","volume":"63","author":"Morgado","year":"2013","journal-title":"Histopathology"},{"key":"10.1016\/j.iac.2023.04.011_bib88","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1182\/blood-2015-03-637728","article-title":"Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis","volume":"126","author":"Blatt","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.iac.2023.04.011_bib89","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.iac.2023.04.011_bib90","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.iac.2023.04.011_bib91","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations","volume":"130","author":"Bodemer","year":"2010","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.iac.2023.04.011_bib92","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.jaci.2022.04.004","article-title":"Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: status 2022","volume":"149","author":"Arock","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2023.04.011_bib93","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41375-021-01406-y","article-title":"Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis","volume":"36","author":"Zanotti","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.iac.2023.04.011_bib94","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/all.14248","article-title":"Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification","volume":"75","author":"Trizuljak","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2023.04.011_bib95","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdu047","article-title":"Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal","volume":"25","author":"Valent","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.iac.2023.04.011_bib96","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000048186","article-title":"Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis","volume":"127","author":"Sperr","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.iac.2023.04.011_bib97","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/jcp.39.6.596","article-title":"Mast cell sarcoma of the larynx","volume":"39","author":"Horny","year":"1986","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.iac.2023.04.011_bib98","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/00000478-200307000-00019","article-title":"Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma","volume":"27","author":"Chott","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.iac.2023.04.011_bib99","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1200\/JCO.2012.41.9549","article-title":"Mast cell sarcoma: a rare and aggressive entity--report of two cases and review of the literature","volume":"31","author":"Georgin-Lavialle","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.iac.2023.04.011_bib100","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaip.2019.01.006","article-title":"Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome","volume":"7","author":"Valent","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.iac.2023.04.011_bib101","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.jaip.2022.05.007","article-title":"Global classification of mast cell activation disorders: an ICD-10-CM-adjusted proposal of the ECNM-AIM consortium","volume":"10","author":"Valent","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856123000450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856123000450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:52:46Z","timestamp":1760179966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856123000450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":101,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0889856123000450"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2023.04.011","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"World Health Organization Classification and Diagnosis of Mastocytosis","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2023.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}